Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition | Zendy

Ikram El Zaoui | Zendy; Maya Bucher | Zendy; Donata Rimoldi | Zendy; Michaël Nicolas | Zendy; Gürkan Kaya | Zendy; Rosanna Pescini Gobert | Zendy; Nicola Bedoni | Zendy; Ann Schalenbourg | Zendy; Sakina Ezziat | Zendy; Léonidas Zografos | Zendy; Serge Leyvraz | Zendy; Nicolò Riggi | Zendy; Carlo Rivolta | Zendy; Alexandre Moulin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition

Author(s) -

Ikram El Zaoui,

Maya Bucher,

Donata Rimoldi,

Michaël Nicolas,

Gürkan Kaya,

Rosanna Pescini Gobert,

Nicola Bedoni,

Ann Schalenbourg,

Sakina Ezziat,

Léonidas Zografos,

Serge Leyvraz,

Nicolò Riggi,

Carlo Rivolta,

Alexandre Moulin

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-26508

Subject(s) - vemurafenib , trametinib , mapk/erk pathway , pi3k/akt/mtor pathway , mek inhibitor , cancer research , selumetinib , melanoma , kinase , v600e , targeted therapy , protein kinase b , phosphorylation , chemistry , mutation , apoptosis , medicine , cancer , biochemistry , metastatic melanoma , gene

To analyze the activity of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinases/mechanistic target of rapamycin (PI3K/mTOR) pathways in benign and malignant conjunctival melanocytic proliferations and explore whether specific inhibitors can suppress growth of conjunctival melanoma (CJM) cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research